603882.SH
Guangzhou Kingmed Diagnostics Group Co., Ltd.
SSE · Healthcare · Medical - Diagnostics & Research · CN
CNY 29.73
−5.17%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 5.9B | 6.0B | 7.2B | 8.5B | 15.5B |
| Cost of Revenue | 3.8B | 3.9B | 4.8B | 5.4B | 8.8B |
| Gross Profit | 2.1B | 2.1B | 2.4B | 3.1B | 6.7B |
| Operating Expenses | |||||
| R&D Expense | 338.5M | 341.3M | 400.5M | 467.1M | 632.6M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 654.8M | 653.0M | 598.0M | 714.6M | 995.5M |
| Selling & Marketing Expense | 852.2M | 874.4M | 930.6M | 1.0B | 1.5B |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 1.9B | 1.9B | 1.9B | 2.2B | 3.1B |
| Cost and Expenses | 5.7B | 5.8B | 6.7B | 7.6B | 11.9B |
| Operating Income (EBIT) | (27.4M) | (129.9M) | (273.2M) | 759.8M | 3.3B |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | (83.2M) | (181.6M) | (438.6M) | 740.3M | 3.3B |
| Income Tax Expense | 12.8M | (3.0M) | (23.9M) | 103.4M | 475.7M |
| Bottom Line | |||||
| Net Income | (102.7M) | (173.2M) | (381.2M) | 643.4M | 2.8B |
| Earnings from Cont. Ops | (96.0M) | (178.6M) | (414.7M) | 636.9M | 2.8B |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (102.7M) | (173.2M) | (381.2M) | 643.4M | 2.8B |
| Per Share | |||||
| Basic EPS | (CN¥0.22) | (CN¥0.37) | (CN¥0.82) | CN¥1.38 | CN¥5.91 |
| Diluted EPS | (CN¥0.22) | (CN¥0.37) | (CN¥0.82) | CN¥1.38 | CN¥5.90 |
| Revenue Per Share | CN¥12.44 | CN¥12.88 | CN¥15.46 | CN¥18.32 | CN¥33.20 |
| Shares | |||||
| Basic Shares Outstanding | 475.5M | 468.2M | 464.9M | 466.2M | 466.1M |
| Diluted Shares Outstanding | 475.5M | 468.2M | 464.9M | 466.2M | 466.1M |
| Profitability Metrics | |||||
| EBITDA | — | 285.4M | 270.4M | 1.3B | 3.9B |
| D&A | — | 415.3M | 543.6M | 559.3M | 503.3M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026